qs-21 has been researched along with Pain* in 2 studies
2 trial(s) available for qs-21 and Pain
Article | Year |
---|---|
Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.
The effects of the adjuvant QS-21 in various formulations on immediate pain on injection after intramuscular injection were evaluated in three Phase I clinical trials in healthy adults. Each trial was designed as a double-blind, randomized, four-way or five-way cross-over study with each subject acting as his/her own control. In the first trial, four formulations designed to evaluate the effect of QS-21 or pH (over a range of 6--7.2) were evaluated: phosphate-buffered saline at pH 6.0 or 7.2, and 50 microg of QS-21 in phosphate-buffered saline at pH 6.0 or 7.2. Thirty-three volunteers received each of the four intramuscular injections in random order separated by approximately 1 week. The volunteers assessed the immediate injection pain from 0 to 10 (none to most pain). The data indicate that the presence of QS-21, but not pH, is associated with transient injection site pain. The second trial, which utilized the same design as the first trial, evaluated formulations of QS-21 in various excipients. Fifteen volunteers received phosphate-buffered saline, QS-21/PBS, QS-21/aluminum hydroxide, and QS-21/4 mg/ml of polysorbate 80. Polysorbate 80, but not aluminum hydroxide, reduced the mean pain score compared to QS-21/PBS. The third trial evaluated formulations of QS-21 in additional excipients. Fifteen volunteers received aluminum hydroxide (without QS-21), QS-21/PBS, QS-21/0.72% benzyl alcohol, QS-21/30 mg/ml of hydroxypropyl-beta-cyclodextrin, and QS-21/8-mg/ml of polysorbate 80. Benzyl alcohol, cyclodextrin, and the higher concentration of polysorbate 80 reduced the pain scores associated with QS-21. Hence, QS-21 is associated with injection pain in simple buffer formulations, but it is possible to improve the acceptability of QS-21-containing formulations through reformulation with certain excipients. Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adjuvants, Immunologic; Adolescent; Adult; Aluminum Hydroxide; Benzyl Alcohol; beta-Cyclodextrins; Cross-Over Studies; Cyclodextrins; Double-Blind Method; Drug Tolerance; Humans; Hydrogen-Ion Concentration; Injections, Intramuscular; Middle Aged; Pain; Polysorbates; Safety; Saponins | 2001 |
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
A melanoma vaccine composed of HLA-A2-restricted peptide YLEPGPVTA (gp100(280)), with or without a modified T-helper epitope from tetanus toxoid AQYIKANSKFIGITEL, has been evaluated in a Phase I trial to assess safety and immunological response. The vaccines were administered s.c. in either of two adjuvants, Montanide ISA-51 or QS-21, to 22 patients with high-risk resected melanoma (stage IIB-IV). Local and systemic toxicities were mild and transient. We detected CTL responses to the gp100(280) peptide in peripheral blood in 14% of patients. Helper T-cell responses to the tetanus helper peptide were detected in 79% of patients and had a Th1 cytokine profile. One patient with a CTL response to gp100 had a recurrence in a lymph node 2 years later; her nodes contained CD8+ cells reactive to gp100(280) (0.24%), which proliferated in response to peptide. The overall survival of patients is 75% (95% confidence interval, 57-94%) at 4.7 years follow-up, which compares favorably with expected survival. Four of 14 patients who completed at least six vaccines subsequently developed metastases, all of which were solitary and surgically resectable. They remain alive and clinically free of disease at last follow-up. Data from this trial demonstrate immunogenicity of the gp100(280) peptide and suggest that immune responses may persist long-term in some patients. The frequency and magnitude of the CTL response may be improved with more aggressive vaccination regimens. Although this Phase I study was not intended to evaluate clinical benefit, the excellent survival of patients on this protocol suggests the possibility of a benefit that should be assessed in future studies. Topics: Adjuvants, Immunologic; Amino Acid Sequence; Cancer Vaccines; CD4-Positive T-Lymphocytes; Cell Division; Cell Line; Cytokines; Epitopes, T-Lymphocyte; Female; Follow-Up Studies; gp100 Melanoma Antigen; Headache; HLA-A2 Antigen; Humans; Hypersensitivity, Delayed; Interferon-gamma; Lymph Nodes; Male; Melanoma; Membrane Glycoproteins; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Neoplasm Staging; Pain; Peptide Fragments; Peptides; Saponins; Skin; Skin Diseases; Skin Tests; Survival Analysis; T-Lymphocytes, Cytotoxic; Tetanus Toxoid; Th1 Cells; Time Factors; Treatment Outcome | 2001 |